Promoted Content
Promoted Content

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Lidocaine,Prilocaine

            Therapeutic Area: Psychiatry/Psychology Product Name: Senstend

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Wanbang Biopharmaceuticals

            Deal Size: $4.0 million Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement December 02, 2020

            Details:

            Under the License Agreement Regent Pacific is now entitled to receive a payment of approximately HK$6.24 million from Wanbang Pharmaceutical, which is payable within 30 business days. NMPA will now formally review Senstend™ for Clinical Trial Approval.